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Hazard communicationa b s t r a c t
Although risk assessment, assessing the potential harm of each particular exposure of a substance, is
desirable, it is not feasible in many situations. Risk assessment uses a process of hazard identiﬁcation,
hazard characterisation, and exposure assessment as its components. In the absence of risk assessment,
the purpose of classiﬁcation is to give broad guidance (through the label) on the suitability of a chemical
in a range of use situations. Hazard classiﬁcation in the EU is a process involving identiﬁcation of the haz-
ards of a substance, followed by comparison of those hazards (including degree of hazard) with deﬁned
criteria. Classiﬁcation should therefore give guidance on degree of hazard as well as hazard identiﬁcation.
Potency is the most important indicator of degree of hazard and should therefore be included in classi-
ﬁcation. This is done for acute lethality and general toxicity by classifying on dose required to cause the
effect. The classiﬁcation in the EU for carcinogenicity and reproductive toxicity does not discriminate
across the wide range of potencies seen (6 orders of magnitude) for carcinogenicity and for developmen-
tal toxicity and fertility. Therefore potency should be included in the classiﬁcation process. The method-
ology in the EU guidelines for classiﬁcation for deriving speciﬁc concentration limits is a rigorous process
for assigning substances which cause tumours or developmental toxicity and infertility in experimental
animals to high, medium or low degree of hazard categories by incorporating potency. Methods are sug-
gested on how the degree of hazard so derived could be used in the EU classiﬁcation process to improve
hazard communication and in downstream risk management.
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There has been a debate for many years about the relative mer-
its of regulation by hazard or by risk (Lofstedt, 2011). Much of the
debate seems to focus on Classiﬁcation and Labelling (C&L) and
what is meant by the term ‘‘intrinsic hazard’’ and by the assertion
that C&L is hazard based and does not take into account exposure.
In contrast, risk assessment takes exposure into account. However,
the source of the controversy which continues to fuel the debate
lies in the downstream consequences of either classiﬁcation or of
risk assessment and that is risk management, more particularly
those aspects of risk management which ﬁnd their way into regu-
lation and legislation in the form of restrictions on use.
There is a well recognised process for assessing the potential
adverse effects of chemicals on health which has been described
in detail by van Leeuwen and Vermieire (2007). The ﬁrst step is
hazard identiﬁcation, identifying the adverse effects a chemical
has the inherent capacity to cause. The next step, effects assess-
ment or hazard characterisation, is the estimation of the response
between dose or level of exposure to a substance and the incidence
and severity of an effect. Exposure assessment is the estimation of
the doses/exposure levels to which human populations are
exposed. Risk assessment or risk characterisation brings together
hazard characterisation and exposure assessment in an estimate
of the incidence and severity of the adverse effects likely to occur
in a human population due to the predicted exposure. Risk man-
agement then follows which is a decision making process that
entails weighing political, social, economic and engineering infor-
mation against risk related information to develop and select the
appropriate response to a potential health hazard.
The full process of chemical risk assessment and risk manage-
ment requires an assessment of the use or uses of the chemical
which relies on detailed knowledge of the use patterns (both
industrial and consumer), emissions, pathways and rates of move-
ment and degradation. It is the use of the substance in the partic-
ular situation or situations which is being assessed. The
classiﬁcation of substances offers a quick and uncomplicated
means of communicating to potential users the potential health
hazard to humans, wildlife or the environment, and therefore is a
valuable tool especially for managing the risk of accidental expo-
sure. Also, in situations where risk assessment is not possible
due to the lack of reliable exposure information, hazard classiﬁca-
tion can help in the risk management of chemicals.
The aim of this paper is to explore ways in which the outcome
of the classiﬁcation process for cancer and for reproductive toxicity
could be improved to better communicate the degree of hazard
which substances may pose.2. Classiﬁcation in the EU
The Globally Harmonised System of Classiﬁcation and Labelling
of Chemicals (GHS, 2013) provides a harmonised basis for globally
uniform physical, environmental and health and safety informa-
tion on hazardous chemical substances and mixtures. The Euro-
pean Commission, the EU Member States and the European
Parliament endorsed the UN recommendation to implement the
GHS in domestic law. In practice the implementation of GHS in
the EU resulted in very little change from the previous process.
Classiﬁcation as deﬁned in the EU Guidance on CLP (ECHA,
2012a) is essentially a process of hazard identiﬁcation and effects
assessment: ‘‘Hazard classiﬁcation is a process involving identiﬁca-
tion of the physical, health and environmental hazards of a sub-
stance or a mixture, followed by comparison of those hazards
(including degree of hazard) with deﬁned criteria in order to arrive
at a classiﬁcation of the substance or mixture.’’ The aim is to pro-vide information which can then be used in risk management,
the EU Guidance states: ‘‘The aim of classiﬁcation and labelling is
to identify the hazardous properties of a substance or a mixture
by applying speciﬁc criteria to the available hazard data (classiﬁca-
tion), and then to provide any appropriate hazard labelling and
information on safety measures.’’
The EU guidance emphasises that: ‘‘Classiﬁcation according to
CLP is based on intrinsic hazards, i.e. the basic properties of a sub-
stance as determined in standard tests or by other means designed
to identify hazards. As C&L is hazard-based, it does not take expo-
sure into consideration in arriving at either a classiﬁcation or
appropriate labelling, unless for speciﬁc exceptions when a sub-
stance can be considered as not being biologically available, such
as the derogation not to label a metal in the massive form.’’ The
controversy lies in the interpretation of whether ‘‘intrinsic hazard’’
means identifying the potential to cause adverse effects and noth-
ing else or whether it includes hazard characterisation. The deﬁni-
tion of the hazard classiﬁcation process provided by ECHA is
unequivocal in specifying a two part process including hazard
characterisation: ‘‘Hazard classiﬁcation is a process involving iden-
tiﬁcation of the physical, health and environmental hazards of a
substance or a mixture, followed by comparison of those hazards
(including degree of hazard).’’ In order to be meaningful classiﬁca-
tion has to provide guidance to determine if a substance or mixture
is suitable for speciﬁc downstream uses. Therefore it must take
into account the degree of the hazard as well as the nature of the
hazard. The degree of hazard is determined by potency, which is
primarily based on the dose causing a speciﬁc toxic effect (type
of hazard). In addition degree of hazard takes into account the
severity of the effect. The incidence, type and magnitude describe
the ‘severity’, meaning how adverse the effect is (ECHA, 2012a).
Chemicals are then placed into categories reﬂecting their degree
of hazard.
This concept has been incorporated into the classiﬁcation of
most toxic effects. Acute toxicity, irritation and corrosivity have
used an estimate of potency to assign a substance to a category.
With acute toxicity, the end point, death, is ﬁxed and the dose
required to cause death is determined and then the substance is
ascribed to one of 4 categories on the basis of its acute lethal
potency. For skin and eye irritation the dose is ﬁxed, but the con-
sequences are scored according to their severity and the substance
assigned to one of three categories as a result based on its irritant
potency. In corrosivity, the dose is ﬁxed, but the duration that the
substance is in contact with the skin or the eye is varied. The
effects are then assessed and the substance is ascribed to a cate-
gory based on the length of exposure required to cause corrosion,
the corrosivity potency.
The classiﬁcation system also incorporates potency in the way it
deals with other types of toxicity, the so-called speciﬁc target
organ toxicity (STOT). The system recognises that many substances
are capable of the hazard of causing damage or adverse effects to
speciﬁc organs or systems. STOT means speciﬁc, target organ tox-
icity arising from a single or repeated exposure to a substance or
mixture. All signiﬁcant health effects that can impair function, both
reversible and irreversible, immediate and/or delayed are included.
However, other speciﬁc toxic effects that are speciﬁcally addressed
(acute toxicity, skin corrosion/irritation, serious eye damage/irrita-
tion, respiratory or skin sensitisation, germ cell mutagenicity, car-
cinogenicity, reproductive toxicity) are not included (ECHA,
2012a). The distinction between the categories in speciﬁc target
organ toxicity is based on the dose level used in the animal studies
in which the adverse effects were seen, with the Category 1 being
reserved for the substances which cause adverse effects at low
doses. The distinguishing dose levels are adjusted using Haber’s
Rule to take into account the duration of dosing as shown in
Table 1.
Table 1
Speciﬁc target organ toxicity values (STOT-SE for single exposure and STOT-RE for
repeat exposure).
Dose (mg/kg/day) STOT-SE and STOT-RE values for different study duration
(oral dosing)




6300 Category1 Category 2 No classiﬁcation
62000 Category 2 No classiﬁcation
>2000 No classiﬁcation
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ductive toxicity differs in that classiﬁcation is in general restricted
to hazard identiﬁcation. The EU criteria are based on the strength
of scientiﬁc evidence that the substance causes cancer or reproduc-
tive toxicity in either humans or laboratory animals. No speciﬁc
considerations are given to the potency of the substance, although
there is a limit dose of 1000 mg/kg bwt/day set for most studies.
The identiﬁcation of individual substances on the basis of the
strength of evidence for carcinogenicity or reproductive toxicity
has resulted in the classiﬁcation of a large number of substances
as carcinogens or reproductive toxicants. However, classiﬁcation
for carcinogenicity and reproductive toxicity does not discriminate
across the wide range of potencies seen (6 orders of magnitude)
(Gold et al., 1989; Muller et al., 2012) and this limits the utility
of the classiﬁcation as a means of providing appropriate hazard
labelling and information on safety measures.
3. Potency of chemicals to cause cancer and reproductive
toxicity
It has been found that the potency of carcinogens and reproduc-
tive toxicants covers a wide range. Gold et al. (1989) examined the
potency of 492 chemicals which had been tested in long term
rodent bioassays for carcinogenicity by calculating the TD50, the
dose calculated to cause an increased incidence of tumours of
50%. They found a range of TD50s which spanned 9 orders of mag-
nitude ranging from 7 ng/kg bwt/day for 2,3,7,8-Tetrachlo-
rodibenzo-p-dioxin to 24.5 g/kg bwt/day for SX Purple. In
addition, the EPA’s IRIS database includes chemicals with a range
of 6 orders of magnitude (EPA). Muller et al. (2012) examined
the LOAELs, NOAELs and ED10s (dose required to cause an
increased incidence of 10%) of the effects which resulted in classi-
ﬁcation of 93 substances for developmental toxicity and effects on
fertility. The range of values spanned 7 orders of magnitude for
developmental toxicity (0.0002 to 2281 mg/kg bwt/day) and 5
orders of magnitude (0.032 mg/kg bwt/day to 940 mg/kg bwt/
day) for fertility. Sanner and Dybing (2005) have a shown a corre-
lation between the potency of chemicals to cause cancer in humans
is related to their potency to cause cancer in rats and mice.
Although there is no systematic review available for reproductive
toxicity, many of the mechanisms involved such as effects on the
endocrine system have been shown to occur in experimental ani-
mals which have been used in the development of such com-
pounds for human therapeutic use which indicates that there
must be a correlation of potency. It is clear that with such wide
ranges of potency it is important to determine and communicate
the degree of hazard as well as the nature of the hazard.
The importance of potency has been recognised in the frame-
work of classiﬁcation of mixtures that contain a hazardous ingredi-
ent with a cancer or reproductive toxicity classiﬁcation.Whether or
not such a classiﬁcation of an ingredient will carry over to the mix-
ture is governed by the concentration limit designated for that
ingredient. The default procedure is to apply general concentrationlimits, which depend on the classiﬁcation category of the substance.
Category 1A (substances known to cause effects in humans) and 1B
(substances presumed to cause effects in humans) substances are
subjected to a limit of 0.1% for carcinogenicity and 0.3% for repro-
ductive toxicity and Category 2 (suspected to cause effects in
humans) substances are subjected to a limit of 1% for carcinogenic-
ity and3% for developmental/reproductive toxicity.However, due to
the fact that the classiﬁcation category does not take potency into
account, the general concentration limits do not reﬂect the potency
of a carcinogen or a developmental/reproductive toxicant in a mix-
ture. As well as the need for a system to reﬂect this wide range of
potencies, there are exampleswhere the question of potency as such
is of particular concern (EC, 1999). The high potency of the sub-
stances such as dimethylsulfate and hexylmethylphosphoramide
or impurities such as TCDD and certain nitrosamines gives rise to
concern and it is possible that a general limit of 0.1% does not ade-
quately express the hazard of a mixture. In other cases, substances
may be classiﬁed although relatively high doses are needed to
induce tumours or reproductive toxicity. In such cases the general
limit may inappropriately express the hazard of a mixture contain-
ing such substances, this time by over-estimating the carcinogenic-
ity or reproductive toxicity of the mixture.
The EU has addressed these issues by the option to derive spe-
ciﬁc concentration limits for carcinogens (EC, 1999) and for repro-
ductive toxicity (ECHA, 2012b) in mixtures. These speciﬁc
concentration limits are established on the basis of the determina-
tion of a dose descriptor for the relevant effect and the subsequent
categorisation into high, medium or low potency. The categorisa-
tion can then be modiﬁed by a number of factors including the
severity of the response. The concentration limits for the substance
are then adjusted in accordance with the potency category. The
limit for high potency substances is reduced by a factor of 10
and the limit for low potency substances is increased by a factor
of 10. The limit for medium potency substances is not changed.
The concerns about the potential miscommunication of the
degree of hazard remain for the overall classiﬁcation because it
does not include a consideration of potency. It has been argued
that this is not part of the classiﬁcation process as agreed under
GHS, subsequently incorporated into the EU regulations, and there-
fore it should not be done. Closer examination of the GHS process
for carcinogenicity can challenge this view. The current classiﬁca-
tion process uses 2 strands to consider the information:
 Strength of evidence
 Weight of evidence.
Strength of evidence – The GHS guidelines (GHS, 2013) for car-
cinogenicity describe the strength of evidence process as involving
the enumeration of tumours in human and animal studies and
determination of their level of statistical signiﬁcance. Sufﬁcient
evidence in animals shows a causal relationship between the agent
and an increased incidence of tumours.
Weight of evidence – The GHS guidelines (GHS, 2013) for car-
cinogenicity describe the weight of evidence as additional consid-
erations, a number of other factors which should be considered
that inﬂuence the overall likelihood that an agent may pose a car-
cinogenic hazard in humans. These factors include:
(a) Tumour type and background incidence.
(b) Multi-site responses.
(c) Progression of lesions to malignancy.
(d) Reduced tumour latency.
(e) Whether responses are in single or both sexes.
(f) Whether responses are in a single species or several species;
(g) Structural similarity to a substance(s) for which there is
good evidence of carcinogenicity.
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(i) Comparison of absorption, distribution, metabolism and
excretion between test animals and humans.
(j) The possibility of a confounding effect of excessive toxicity
at test doses.
(k) Mode of action and its relevance for humans, such as cyto-
toxicity with growth stimulation, mitogenesis, immunosup-
pression, mutagenicity.
The guidelines also suggest that methods for estimating
potency should be developed.
ECETOC (McGregor et al., 2010) described a process for using
the GHS guidelines for carcinogenicity which incorporates both
strength of evidence and weight of evidence in deciding upon the
classiﬁcation for a chemical. It poses a series of 7 questions:
 Has the relevant form of the substance been tested? (strength of
evidence)
 Is the study design relevant to human exposure, including dose
and route of exposure? (strength of evidence)
 Is there a substance related response? (strength of evidence)
 Is the target tissue exposure relevant to humans? (weight of
evidence)
 Can a Mode of Action be established and if so is it relevant to
humans? (weight of evidence)
 What is the potency? (weight of evidence)
The guidelines for developmental/reproductive toxicity do not
contain such a clear distinction between strength of evidence
and weight of evidence; however it is a principle which can also
be usefully be applied to these areas as well.
To summarise: strength of evidence = degree of association
between chemical exposure and carcinogenicity or reproductive
toxicity (integrity of the test system, strength of correlation based
on comparison with concurrent and historic control values and
clarity of dose response).
Weight of evidence = other factors which inﬂuence level of con-
cern (human relevance, severity and dose response).
It is clear that an indication of the amount of chemical required
to cause the adverse effects in classiﬁcation for carcinogenicity and
for developmental/reproductive toxicity would improve hazard
communication.4. Methodology for assessing potency
The methodology described in the EU Guidance for the deriva-
tion of speciﬁc concentration limits for carcinogens (EC, 1999)
allows the derivation of carcinogen potency dose descriptors and
the subsequent allocation of the chemical to high, medium or
low potency groups. Potency is deﬁned in the EU Guidance as the
magnitude, with respect to dose, of the carcinogenic activity of a
chemical in the species under consideration.
Several methods for deriving the dose descriptor were assessed.
The T25 method was selected for potency ranking with several
advantages in comparison to the TD50 and other methods being
cited in the EU Guidance. First, it does not require (complex) com-
puter modelling after establishment of a signiﬁcant increase in
tumour incidence. Also, T25 values are much more likely to be
within the range of the experimental data and the use of data from
the lowest dose giving a signiﬁcant response, should in most
instances reduce the problem of intercurrent mortality to an
acceptable degree. Finally, the data proﬁle needed for calculating
a T25 value has to be less speciﬁc, e.g. time to tumour data are
not needed. It is recognized that the potential loss of precision does
not match the many order of magnitude differences incarcinogenic potencies which have been found between high and
low potency substances in rodents. It is acknowledged that their
are reservations about the use of the T25 for risk estimation as it
does not explore the lower end of the dose response (EC, 1999;
Roberts et al., 2001).
The EU guidance states: ‘‘The subdivision into the three potency
groups is performed based on a tumorigenic dose descriptor.
Among several possible descriptors, T25 is selected, the dose giving
a tumour incidence of 25% in experimental animals after correction
for the spontaneous incidence. Carcinogens of high potency are
those with a T25 value which is: 61 mg/kg bodyweight/day, those
of medium potency when: 1 mg/kg bw/day < T25 value 6 100 mg/
kg bw/day, and those of low potency when the T25 value is:
>100 mg/kg bw/day. In addition to subdividing carcinogens by
the use of the tumorigenic dose descriptor, T25, several other ele-
ments bearing on tumorigenic potency (dose–response relation-
ships, site/species/strain/gender activity, mechanism including
genotoxicity, mechanistic relevance to humans, toxicokinetics
and other elements relevant to potency classiﬁcation) are taken
into consideration, which thereby may modify the potency preli-
minary evaluation.’’
The purpose of the modifying factors is to bring a structured
way of applying expert judgment to the process of assigning chem-
icals to the potency categories by considering a number aspects
which could mean that the chemical should be considered to be
either more potent or less potent than indicated by the T25. The
use of the modifying factors process is especially important when
the T25 value falls close to a boundary between categories. These
process and the modifying factors described in detail in the guid-
ance document (EC, 1999), and they are summarized here.
4.1. Dose–response relationships
A supralinear dose–response relationship may indicate higher
relative potency at lower doses than for a linear dose response.
This could move chemicals near potency borders into a higher
potency group. A related problem arises when the tumour fre-
quency is very high at the lowest dose tested. In such cases a max-
imal tumour response may already have been reached and the
calculated T25 might be higher than that which would have been
found if lower experimental doses had been used. In such cases
substances near the potency borders may likewise be moved into
a higher potency group.
A sublinear relationship may indicate lower relative potency at
lower doses than at higher doses. This could move chemicals near
the potency borders into a lower potency group.
4.2. Site/species/strain/gender activity
Potent carcinogens tend to be effective in common, multiple tis-
sue sites and across species and genders. Thus, chemicals near the
potency borders may be moved to a higher potency group for car-
cinogens expressing this behaviour.
Low potency carcinogens tend to only be active in a single spe-
ciﬁc tissue site in a single gender of a single species or only at a sin-
gle site with a high spontaneous tumour incidence.
Thus, chemicals near the potency borders may be moved to a
lower potency group for carcinogens expressing this behaviour.
4.3. Mechanisms including genotoxicity
It is recommended to use information on mechanism including
genotoxic activity as one element in conjunction with the other
elements. Genotoxic chemicals are deﬁned in the EU Guidance
(EC, 1999) as chemicals that fulﬁll the criteria as EU Category 2
mutagens (positive evidence obtained from experiments in
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obtained from somatic cell mutagenicity tests in vivo, in mammals
or other in vivo somatic cell genotoxicity tests which are supported
by positive results from in vitro mutagenicity assays).
Lack of genotoxic activity in appropriate, well-performed tests
may indicate a lower carcinogenic potency and may thus move a
chemical near the potency borders to the next lower potency
group, normally from intermediate to low.
4.4. Mechanistic relevance to humans
For experimental carcinogenic chemicals where the available
studies of mechanisms are so convincing that the chemical obvi-
ously does not represent a cancer hazard for humans, the chemical
should not be classiﬁed for carcinogenic properties and would not
be subjected to this process. The WHO/IPCS Human Relevance
Framework gives guidance on how relevance to humans should
be assessed (Meek et al., 2014).
4.5. Toxicokinetics
In most instances, data will not be available allowing a compar-
ison of the toxicokinetic behaviour of a carcinogen between
humans and the test animal. However where this information is
available it can be used to determine whether a chemical close
to the border should be moved because of knowledge that the test
animal is either exposed to a higher or lower internal dose of the
relevant metabolite. Thus, in the absence of comparative data, it
is assumed that the carcinogen shows similar toxicokinetic behav-
iour in humans and in test animals.
4.6. Other elements relevant to potency evaluation
Other types of information may be utilized in deriving a ﬁnal
allocation of a carcinogen to a potency group. Structure–activity
considerations may give important indications on the potency, by
examining the potency of structurally related carcinogens.
As described above, the categorisation into high, medium or low
potency is then used to ascribe a speciﬁc concentration limit for
the concentration of the chemical above which the mixture con-
taining the chemical must be labelled for carcinogenicity. These
speciﬁc concentration limits vary by a factor of 10 depending on
the potency category.
Guidance on the derivation of speciﬁc concentration limits for
developmental/reproductive toxicity has been included in the EC
Guidance version 3.0 (ECHA, 2012b). An approach similar to that
for carcinogenicity has been adopted and it is based largely on
the work of Muller et al. (2012). The guidelines provide a deﬁnition
and a commentary:
‘‘Reproductive toxicity potency is deﬁned as the dose which
induces reproductive toxic effects with a speciﬁc type, incidence
and magnitude, considering the study design in terms of species
and strain, exposure route, exposure duration, exposure window
in the life cycle, and possible concomitant parental toxicity.
According to this deﬁnition ‘Potency’ is primarily based on
applied dose and can be modiﬁed by consideration of ‘severity’.
Within this deﬁnition the dose is deﬁned as the amount of chem-
ical to which the animals or humans that showed the effect (mean-
ing type, incidence and magnitude) were exposed on an mg/kg bw/
day basis. The incidence is the proportion of animals or humans
that showed the effect. The type of effect describes which property
of an organ or system of the animal or human is affected and the
magnitude describes the level of change compared to the control.
Together, the incidence, type and magnitude describe the ‘severity’
of the effect, meaning how adverse the effect or combination of
effects is. With speciﬁc incidence, type and magnitude (togetherspeciﬁc severity) a comparable level of severity is indicated for dif-
ferent effects. The working deﬁnition above allows potency to be
deﬁned at different levels of speciﬁc severity, for example at the
ED10 and the LOAEL (Lowest Observed Adverse Effect Level), and
for different type of effects. Therefore, several possible estimates
for potency were investigated’’ (ECHA, 2012b).
Muller et al. (2012) suggested the use of the ED10 as a measure
of potency for developmental/reproductive toxicity effects which
lead to classiﬁcation on strength of evidence in a similar way to
the use of the T25 value for tumours. They applied the principle
that the majority of chemicals being classiﬁed should fall into
the medium range and this principle led them to use 4 mg/kg/
day as their boundary between high and medium potency, and
400 mg/kg/day as the boundary between medium and low
potency. There is also provision to reduce the speciﬁc concentra-
tion limit for chemicals where the ED10 is 10 or 100 times lower
than the 4 mg/kg/day boundary for high potency. There is a similar
process of considering the application of modifying factors espe-
cially when the ED10 is close to a boundary between potency cat-
egories. The factors are:
 Type of effect/severity
 Data availability
 Dose–response relationship
 Mode or mechanism of action
 Toxicokinetics
 Bio-accumulation of chemicals
While most modifying factors would result in a higher potency
group than the preliminary one, also the opposite could occur.
Some modifying factors are of a more qualitative nature. When
applied, they will simply point to a potency group different from
the one resulting from the preliminary assessment.
Other modifying factors might be quantiﬁable, at least on a
semi-quantitative scale. In such cases, a potency group higher (or
lower) than the preliminary one should be chosen if the estimated
size of the modifying factor exceeds the distance of the preliminary
ED10 to the border of the relevant (higher or lower) adjacent
potency group. There is detailed guidance on the application of
the modifying factors in the CLP Guidance (ECHA, 2012b), the main
points from the guidance are:4.7. Type of effect/severity
The type of effect(s) resulting in the same classiﬁcation as
reproductive toxicant differs between chemicals. Some effects
could be considered as more severe than others, however, ranking
different effects based on their severity is controversial and it is
difﬁcult to establish criteria. In addition the effects can become
more severe as the dose levels are increased e.g. from variations
to malformations or small changes in testes histopathology
through effects on fertility to an irreversible and complete absence
of fertility. However, the full spectrum of effects usually lies within
a range of doses which is smaller than the range of the potency
groups. The classiﬁcation is usually based on the most severe
effects and the most severe effects are usually observed at the low-
est dose with reproductive effects (Muller et al., 2012). Therefore, a
differentiation between types of effects is considered to have lim-
ited added value. Exceptions can be dealt with on a case by case
basis.4.8. Data availability
There are several aspects to this modifying factor, some of
which are:
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and therefore certain parameters have not been evaluated,
 limited data availability where the spectrum of evaluated
parameters is sufﬁcient, but only studies with limited duration
are available, and
 limited data availability where only a LOAEL, but no NOAEL
could be identiﬁed.
4.9. Dose–response relationship
The ED10 will in most cases probably be in the same range as
the NOAEL and LOAEL.
However, in cases of a shallow dose effect relationship curve,
the LOAEL may sometimes be clearly below the ED10. In such sit-
uations, if a chemical would fall into a lower potency group based
on the ED10 but into a higher potency group based on the LOAEL
then the higher potency group should be used for that chemical.
4.10. Mode or mechanism of action
It is assumed that effects observed in animal studies are rele-
vant to humans. Where it is known that the mode or mechanism
of action is not relevant for humans or is of doubtful relevance to
humans, this should have been taken into account in the classiﬁca-
tion and should not be used again as a modifying factor for
potency.
However, quantitative differences in toxicodynamics can be
taken into account when not already taken into account in the clas-
siﬁcation. In cases where mechanistic information shows a lower
sensitivity in humans than in experimental animals, this maymove
chemicals which are close to the potency boundaries to a lower
potency group. In cases where mechanistic information indicates
a higher sensitivity in humans than in experimental animals, this
may move chemicals near the potency boundaries to a higher
potency group.
4.11. Toxicokinetics
The toxicokinetics of a chemical can differ between the tested
animal species and humans. Where a difference in toxicokinetics
is known between the test animal and humans this should be
taken into account when determining the potency group of a
substance.
4.12. Bio-accumulation of substances
The study design of, for example, developmental studies is
aimed at exposure only during development. For chemicals which
bio-accumulate, the actual exposure in the time window of sensi-
tivity for some developmental effects may therefore be much
lower than when exposure at the same external dose level would
have started long before the sensitivity window.
5. Classiﬁcation for mutagenicity
The classiﬁcation of chemicals for mutagenicity also does not
take into account potency. Classiﬁcation is done on a strength of
evidence basis from the results of a range of in vitro and in vivo
assays. In addition there is no provision for the derivation of spe-
ciﬁc concentration limits for mixtures. The EU CLP Guidance
(ECHA, 2012a) explains that ‘‘There are several reasons why it is
considered impossible to set SCLs for mutagens without a compre-
hensive guidance, one of them being that mutagenicity tests have
not been speciﬁcally developed for the derivation of a quantitative
response. Moreover, different mutagenicity tests have differentsensitivities in detecting mutagens. Thus, it is very difﬁcult to
describe the minimum data requirements which would allow a
standardized SCL derivation. Another drawback in practice is that
the results obtained for the most part do not offer sufﬁcient infor-
mation on dose–response, especially in the case for in vivo tests. In
conclusion, the possibility to set SCL for germ cell mutagenicity is
therefore not considered possible in the process of self-classiﬁca-
tion as there is no standardized methodical approach available
which adequately takes into account all relevant information.’’ It
is therefore not possible to bring potency consideration into the
classiﬁcation of chemicals for mutagenicity at this point in time.6. Bringing degree of hazard into classiﬁcation
The C&L potency categorisations for carcinogenicity and for
developmental and reproductive toxicity as developed and
described in the ECHA Guidelines (EC, 1999; ECHA, 2012a,b) repre-
sent a rigorous and well thought process for assessing the degree of
hazard of chemicals which cause cancer or reproductive toxicity in
laboratory animals. The potency categories which are derived from
this process could be used as an aid to improving hazard commu-
nication in overall classiﬁcation of the chemical in addition to their
primary purpose in the derivation of speciﬁc concentration limits.
A short verbal description which incorporates both the hazard
identiﬁcation and the degree of hazard can be derived quite
simply:
 Presumed human with high potency
 Presumed human with medium potency
 Presumed human with low potency
 Suspected human with high potency
 Suspected human with medium potency
 Suspected human with low potency.
These short verbal descriptions provide a transparent and con-
cise means of communicating the hazard. It is recommended that
these verbal descriptions should be used wherever possible,
including in downstream risk management and communication
processes.
However there may be situations where a coded categorisation
is required. This could be done in 2 ways:
 By adding a potency sufﬁx to the existing classiﬁcation catego-
ries (‘‘Supplementary classiﬁcation category’’)
 By adding potency as additional classiﬁcation criterion and
keeping the existing classiﬁcation categories (‘‘Integration into
overall classiﬁcation category’’).
Degree of hazard as a supplementary classiﬁcation category could
be achieved in a similar manner. The chemical would ﬁrst be clas-
siﬁed in the current way using a strength of evidence approach
based on the strength of the association between the chemical
and the incidence of tumours or developmental/reproductive
effects and an assessment of human relevance. No further assess-
ment would be required for chemicals which are not classiﬁed,
including those considered to be non-relevant to humans. Then
those chemicals in categories 1A, 1B or 2 would be assessed as
described for the derivation of speciﬁc concentration limits and
assigned to a potency category. This potency categorisation would
then be added as a subscript as shown in Table 3. This method
would recognise the two components which give rise to concern
for adverse health effects; the strength of evidence that the effect
could be caused by the chemical and the weight of evidence on
its degree of hazard or potency recognising that higher potency
increases concern. It would allow both hazard identiﬁcation and
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the primary classiﬁcation indicating the hazard identiﬁcation and
the sufﬁx indicating the hazard characterisation as it is a codiﬁed
version of the verbal two part descriptor.
Integration of degree of hazard into the overall classiﬁcation is
similar to the method proposed by ECETOC (McGregor et al.,
2010). The chemical would ﬁrst be the subject of a strength of evi-
dence assessment as in the current system and placed tentatively
into the categories of presumed, suspected or none. This would
include an assessment of relevance. There would be no require-
ment for further assessment if a human non-relevance has been
established and the chemical would be classiﬁed as a non-carcino-
gen. For those chemicals where non-relevance cannot be estab-
lished, an assessment of potency as described in the CLP
Guidance (ECHA, 2012a) would be carried out. Bringing in the
potency determination as described by the EU into the overall clas-
siﬁcation would then be derived as shown in Table 2. The resulting
classiﬁcation would recognise that there are 2 major components
contributing to concern for adverse health effects; the strength of
evidence that the effect could be caused by the chemical and the
weight of evidence on its degree of hazard or potency recognising
that higher potency increases concern. This process results in a
classiﬁcation which is an integration of both hazard identiﬁcation
and hazard characterisation and incorporates the degree of hazard
which is called for in the deﬁnition of classiﬁcation. However, it
involves the loss of some transparency in communication because
the classiﬁcation integrates the two components which give rise to
concern for adverse health effects; the strength of evidence that
the effect could be caused by the chemical and the weight of
evidence on its degree of hazard or potency recognising that higher
potency increases concern (see table 4).
Fig. 1 is a ﬂow diagram of how these processes would operate. It
shows a two step process in which ﬁrst the strength of evidence for
hazard identiﬁcation is assessed and then the degree of hazard is
assessed for presumed or suspected carcinogens or reproductive
toxicants. The process is primarily focused on carcinogenicity or
reproductive toxicity identiﬁed by the use of experimental
animals, however it could also be applied to known human carcin-
ogens or reproductive toxicants where laboratory animal studies
have also been carried out. Accurate and reliable potency estimatesTable 2
Proposed categorisation to allow communication of both hazard
hazard based on weight of evidence using EU potency determinat
Hazard identiﬁcation
assessment categorisation
Degree of hazard cate
High
Carc < 1 mg/kg





Proposed categorisation integrating hazard identiﬁcation based on
evidence using EU potency determination.
Hazard identiﬁcation
assessment categorisation
Degree of hazard cate
High
Carc < 1 mg/kg
Repr < 4 mg/kg
Known 1A
Presumed 1B
Suspected 1Bbased upon human data have preference above those based on ani-
mal data. However, there are several difﬁculties in establishing
reliable human exposure doses (Allen et al., 1988). In spite of the
obvious species relevance, signiﬁcant human epidemiological data
are not available for most chemicals. (See table 5)
The impact of these proposed classiﬁcation schemes has been
explored by the use of examples. The examples are based on those
described in the EU guidance notes for setting SCLs for carcinoge-
nicity (EC, 1999) and for developmental/reproductive toxicity
(ECHA, 2012b). The examples are summarised in Tables 6 and 7
and they are described in more detail in Appendices 1 and 2. In
the guidance document for carcinogenicity no strength of evidence
categorisation was given for the examples, however the examples
have been given a categorisation based on EU guidance. The cate-
gorisation for degree of hazard and potency provided in the exam-
ples has not been changed. In the examples for developmental/
reproductive toxicity, categorisation for hazard identiﬁcation by
strength if evidence is shown and this has not been changed. The
categorisation for degree of hazard by weight of evidence assess-
ment provided in the examples has also not been changed. For
examples 3b for carcinogenicity and examples 4b and 4c for devel-
opmental/reproductive toxicity, the dose levels for the examples
have been changed to illustrate the impact of higher or lower
potency with the same effects, i.e. only the potency has changed.
Tables 6 and 7 show the comparison of the three classiﬁcation
methods: the current method which does not take into account
degree of hazard; the integratedmethod which adjusts the category
by taking into account the degree of hazard; and the supplemental
method which assigns a sufﬁx to indicate the degree of hazard.
It will be seen that the current method assigns the same cate-
gory to chemicals regardless of their degree of hazard or potency,
and thus does not communicate the overall hazard. The integrated
method offers some improvement in providing a better indication
of the degree of hazard. However using this method, it is not pos-
sible to distinguish between chemicals with the following full haz-
ard descriptions which would all be categorised as 1B:
 Presumed human with high potency
 Presumed human with medium potency




Carc 1 < 100 mg/kg Carc > 100 mg/kg




strength of evidence and degree of hazard based on weight of
gorisation
Medium Low
Carc 1 < 100 mg/kg Carc > 100 mg/kg




Fig. 1. Process for deriving hazard identiﬁcation and degree of hazard categories.
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egorised as 2 with the full hazard descriptions of:
 Suspected human with medium potency
 Presumed human with low potency.
The supplemental method provides a categorisation which
allows both the strength of evidence about hazard identiﬁcation
and the degree of hazard to be communicated. Chemicals which
differ in hazard identiﬁcation and/or degree of hazard do not end
up in the same category as is the case with the current method
and with the integrated method.
The supplemental method provides a means to communicate
both the hazard and identiﬁcation and degree of hazard and there-
fore would be the better method of communication. The integrated
method does offer some improvement over the current system in
that it is better at highlighting chemicals of high concern than
the current method. As it uses the same category nomenclature
as the present system it could be used as a transition towards
transparency and better communication of the hazards of
chemicals.
However, it is suggested that more use is made in hazard com-
munication and downstream risk management of the short verbal
descriptor than of the overall category assignment. The short ver-
bal descriptor has an element which indicates the strength of evi-
dence that the chemical is capable of causing the adverse effect of
concern: ‘‘Presumed’’ or ‘‘Suspected’’ and an element which reﬂects
the degree of hazard ‘‘with high potency’’, ‘‘with medium potency’’
or ‘‘with low potency’’. The supplemental method provides a code
to represent the verbal descriptors. Bringing degree of hazard into
the process has already been used to overcome the difﬁculties of
hazard communication in the setting of limits for chemicals in
mixtures and it could also be used to overcome difﬁculties in other
aspects of hazard communication and risk management.Table 4














mice at 9.5 mg/kg/day
Presumed 2.4 Mode of action, lack of lower dose,
tumour type – modify
High Current: presumed human carcin-
ogen: 1B
Integrated: presumed human car-
cinogen with high potency: 1B
Supplemental: presumed human
carcinogen with high potency:
1BHIGH
Medium
2 Brain gliomas at 2.5
mg/kg/day rats
Presumed 1.9 Mode of action, lack of lower dose,
tumour type – modify
High Current: presumed human carcin-
ogen: 1B
Integrated: presumed human car-
cinogen with high potency: 1B
Supplemental: presumed human
carcinogen with high potency:
1BHIGH
Medium
3 Liver carcinomas rats and
mice at 50–200
mg/kg/day
Suspected 74.4 Lack of genotox, presence of toxicity,
comparative metabolism – Modify
Low Current: suspected human carcin-
ogen: 2
Integrated: suspected human car-
cinogen with low potency: N
Supplemental: suspected human
carcinogen with low potency:
2LOW
Medium
3b Liver carcinomas kidney
tumours rats at 0.1
mg/kg/day
Suspected 0.074 Lack of genotox, presence of toxicity,
comparative metabolism suggest
modiﬁcation but very low T25 leads
to – no grounds to modify
High Current: suspected human carcin-
ogen: 2
Integrated: suspected human car-
cinogen with high potency: 1B
Supplemental: suspected human















1 Post implantation loss, malformations in rats
dose range 20–180 mg/kg/day
Presumed 89.8 No grounds
to modify
Medium Current: presumed human reproductive
toxicant: 1B
Integrated: presumed human reproductive
toxicant with medium potency: 1B
Supplemental: presumed human reproduc-
tive toxicantreproductive toxicant with
medium potency: 1BMED
Medium
2 Skeletal malformations in rabbits dose range
25–50 mg/kg/day
Presumed 33 No grounds
to modify
Medium Current: presumed human reproductive
toxicantreproductive toxicant: 1B
Integrated: presumed human reproductive
toxicantreproductive toxicant with med-
ium potency: 1B
Supplemental: presumed human reproduc-
tive toxicantreproductive toxicant with
medium potency: 1BMED
Medium
3 Developmental delay and testicular in male rats
dose range 50–750 mg/kg/day
Presumed 416 No grounds
to modify
Low Current: presumed human reproductive
toxicantreproductive toxicant: 1B
Integrated: presumed human reproductive
toxicantreproductive toxicant with low
potency: 2
Supplemental: presumed human reproduc-
tive toxicantreproductive toxicant with
medium potency: 1BLOW
Low
4 Repeat dose studies, testicular lesions – single
dose 660 mg/kg/day also seen in inhalation
study at 2.9 mg/l
Suspected 132 No grounds
to modify
Medium Current: suspected human reproductive
toxicantreproductive toxicant: 2
Integrated: suspected human reproductive
toxicantreproductive toxicant with med-
ium potency: 2
Supplemental: suspected human reproduc-
tive toxicantreproductive toxicant with
medium potency: 2MED
Medium
4b Repeat dose studies, testicular lesions at
1000 mg/kg NOAEL 500 mg/kg
Suspected 750 No Grounds
to modify
Low Current: suspected human reproductive
toxicantreproductive toxicant: 2
Integrated: suspected human reproductive
toxicant with low potency: N
Supplemental: suspected human reproduc-
tive toxicant with low potency: 2LOW
Low
4c Repeat dose studies, testicular lesions at 1 mg/
kg NOAEL 0.5 mg/kg
Suspected 0.75 No Grounds
to modify
High Current: suspected human reproductive
toxicant: 2
Integrated: suspected human reproductive
toxicant with high potency: 1B
Supplemental: suspected human reproduc-
tive toxicant with high potency: 2HIGH
High
Table 6























C. Hennes et al. / Regulatory Toxicology and Pharmacology 70 (2014) 457–467 465There is a problem with labelling in that it does not communi-
cate the hazard well. The same hazard statement ‘‘May Cause Can-
cer’’ is used for all Category 1B carcinogens regardless of their
degree of hazard or potency. This is in contrast to those chemicals
which can cause death after a single dose where the dose required
is reﬂected in the hazard statement which describes them as ‘‘Fatal
if Swallowed’’ for those of high potency, ‘‘Toxic if Swallowed’’ for
those of medium potency or ‘‘Harmful if Swallowed’’ for those with
low potency. All of these categories are determined by the dose at
which the chemical causes fatality in laboratory animals. The cur-
rent scheme derived from GHS and adopted by the EU for carcino-
genicity and for reproductive toxicity does not allow this
differential communication. This issue would be improved by the
adoption of either the integrated scheme or the supplemental
scheme for incorporating degree of hazard.
Adopting the supplemental scheme would require the introduc-
tion of new hazard phrases which would indicate the potency of
the chemical. The existing hazard phrases could be used with a
supplement, for example ‘‘Limited Exposure May Cause Cancer’’
for 1B with high potency, ‘‘May Cause Cancer’’ for 1B with medium
potency and ‘‘Prolonged High Exposure May Cause Cancer’’ for 1B
Table 7































466 C. Hennes et al. / Regulatory Toxicology and Pharmacology 70 (2014) 457–467with low potency. The same supplementary phrases could be used
with the other categories carcinogenicity and reproductive toxicity
as shown in Table 8.
Adoption of the integrated scheme would mean that the hazard
phrase May Cause Cancer would be reserved for those of high or
medium potency. Those originally categorised as 1B through the
strength of evidence but with low potency would receive the
phrase Suspected of Causing Cancer. This could be achieved within
the existing scheme.
The second consequence of C&L is the relation to other EU leg-
islation which relies on certain classiﬁcation aspects. The conse-
quences of classiﬁcation can be greater than a hazard label and
may have a direct effect on risk management.
Under REACH, classiﬁcation of a chemical as mutagenic, carcin-
ogenic or toxic to reproduction (CMR) may lead to restrictions andTable 8
Examples of revised hazard phrases using the supplemental method of incorporating degr
Hazard identiﬁcation
assessment categorisation
Degree of hazard categorisation
High Med
Carc < 1 mg/kg Carc
Repr < 4 mg/kg Repr
Known Carc 1AHigh 1AMe
Limited exposure may cause cancer May
Presumed Carc 1BHigh 1BMe
Limited exposure may cause cancer May
Suspected Carc 2High 2Med
Limited exposure suspected of causing
cancer
Susp
Known Repr 1AHigh 1AMe




Presumed Repr 1BHigh 1BMe




Suspected Repr 2High 2Med
Limited exposure Suspected of damaging
fertility or the unborn child
Susp
or ththe need to apply for authorisations (EC) No 1907/2006). The cos-
metics Regulation (EC) 1223/2009 prohibits use of CMR, category
1A, 1B and 2 substances unless, a favorable opinion is available
from the Scientiﬁc Committee on Consumer Safety for the given
substance under the given exposure and use concentration, and,
for 1A and 1B substances if compliant with food safety require-
ments. According to the European pesticide Regulation (EC)
1107/2009 or the EU Biocides Regulation 528/2012, CMR classiﬁca-
tions in Cat. 1A and 1B preclude approval of the respective sub-
stance as an active substance, safener, or synergist in plant
protection products or biocidal products.
These downstream risk management processes should be
reviewed as a consequence of the change to classiﬁcation for car-
cinogenicity and reproductive toxicity which are being suggested
in this paper. If the supplementary approach were to be adopted
then the risk management processes would have to be adjusted
to take into account the different degrees of hazard. For instance,
chemicals categorised as 1BLOW would not be the subject to the
same restrictions as is currently applied to all chemicals catego-
rised as 1B. However, if the integrated system were to be adopted
then the downstream risk management process could remain lar-
gely unchanged as chemicals with low potency would no longer
be classiﬁed as category 1B but as category 2. While the risk man-
agement process could remain largely unchanged when adopting
the integrated system, the consequences for chemical use in prod-
ucts are signiﬁcant if the evaluation of the degree of hazard leads
to a re-categorisation from 1B to 2 and from 2 to 1B and if these
categories are regulated differently by downstream regulations.7. Conclusion
Although risk assessment, assessing the safety of each particu-
lar exposure of a chemical, is desirable, it is not feasible in many
situations. Risk assessment uses a process of hazard identiﬁcation,
hazard characterisation, and exposure assessment as its compo-
nents. In the absence of risk assessment, the purpose of classiﬁca-
tion is to give broad guidance on the suitability for a chemical in a
range of use situations. Hazard classiﬁcation is a process involving
identiﬁcation of the hazards of a chemical, followed by comparison
of those hazards (including degree of hazard) with deﬁned criteria
in order to arrive at a classiﬁcation of the chemical. Classiﬁcation
should therefore give guidance on degree of hazard as well asee of hazard into classiﬁcation.
ium Low
1 < 100 mg/kg Carc > 100 mg/kg
4 < 400 mg/kg Repr > 400 mg/kg
d 1ALow
cause cancer Prolonged high exposure may cause cancer
d 1BLow
cause cancer Prolonged high exposure may cause cancer
2Low
ected of causing cancer Prolonged high exposure suspected of causing
cancer
d 1ALow
damage fertility or the
rn child
Prolonged high exposure may damage fertility or
the unborn child
d 1BLow
damage fertility or the
rn child
Prolonged high exposure may damage fertility or
the unborn child
2Low
ected of damaging fertility
e unborn child
Prolonged high exposure suspected of damaging
fertility or the unborn child
C. Hennes et al. / Regulatory Toxicology and Pharmacology 70 (2014) 457–467 467hazard identiﬁcation. Potency is the most important indicator of
degree of hazard and should therefore be included in classiﬁcation.
This is done for acute lethality and general toxicity by classifying
on dose required to cause the effect. The classiﬁcation for carcino-
genicity and developmental/reproductive toxicity does not dis-
criminate across the wide range of potencies seen (6 orders of
magnitude). Therefore potency should be included in the classiﬁca-
tion process for carcinogenicity and developmental/reproductive
toxicity. The methodology in the EU guidelines for classiﬁcation
for deriving speciﬁc concentration limits is a rigorous process for
assigning chemicals which cause tumours or developmental toxic-
ity in animals to high, medium or low potency categories. Methods
are suggested on how the degree of hazard could be used in the
classiﬁcation process to improve hazard communication and
downstream risk management.
Declaration of interest
This paper was prepared by a Task Force of the European Centre
for Ecotoxicology and Toxicology of Chemicals (ECETOC). ECETOC
is a scientiﬁc, non-proﬁt making, non-commercial association with
a mission to act as an independent, peer-reviewed technical
resource to all concerned with the assessment of health effects
and environmental impact of chemicals. It is ﬁnanced by its mem-
bership, which comprises some 40 of the leading companies with
interests in the manufacture and use of chemicals. For this Task
Force, ECETOC paid an honorarium to Dr. Monika Batke and reim-
bursed her for travel expenses relating to the Task Force. Dr. John
Doe’s participation in the Task Force was supported ﬁnancially
by Syngenta Ltd, although Dr. Doe has sole responsibility for the
writing and contents of the paper. All other authors participated
in the Task Force in the normal course of their employment afﬁli-
ation as shown on the ﬁrst page. The employers that are commer-
cial entities produce and market products that are subject to
regulation by National and International authorities that may con-
sider the guidance given in this paper. The authors have sole
responsibility for the writing and contents of the paper.
Acknowledgments
It is a pleasure to acknowledge the advice and assistance from
Dr. M Battalora, Du Pont; Dr. S Jacobi, Albemarle; Dr. S Felter,
Procter and Gamble; Dr. L Meisters, Du Pont; Dr. N Moore, Penman
Consulting and Dr. S Tozer, Procter and Gamble. We also acknowl-
edge the advice received from the ECETOC Stewards Professor HGreim, Technical University of Munich and Dr. B van Ravenzwaay,
BASF.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.yrtph.2014.07.
022.
References
Allen, B.C., Crump, K.S., Shipp, A.M., 1988. Correlation between carcinogenic
potency of chemicals in animals and humans. Risk Anal. 8, 531–544.
EC, 1999. Guidelines for setting speciﬁc concentration limits for carcinogens in
Annex 1 of Directive 67/548/EEC inclusion of Potency Considerations.
Commission Working Group on the Classiﬁcation and Labelling of Dangerous
Substances.
ECHA, 2012a. Guidance on the application of the CLP criteria. Guidance to
Regulation (EC) No 1272/2008 on classiﬁcation, labelling and packaging (CLP)
of substances and mixtures. Version 3.0 November 2012.
ECHA, 2012b. Section 3.7.2.5 Setting of speciﬁc concentration limits in Guidance on
the application of the CLP criteria. Guidance to Regulation (EC) No 1272/2008
on classiﬁcation, labelling and packaging (CLP) of substances and mixtures.
Version 3.0 November 2012.
EPA, IRIS US Environmental Protection Agency Integrated Risk Information System
http://www.epa.gov/iris/.
GHS, 2013. United Nations Globally Harmonized System of Classiﬁcation and
Labelling of Chemicals (GHS, Rev. 5) Sections 3.6.2.4 & 5 Carcinogenicity.
Gold, L., Slone, T., Bernstein, L., 1989. Summary of carcinogenic potency and
positivity for 492 rodent carcinogens in the carcinogenic potency database.
Environ. Health Perspect. 79, p259–p272.
Lofstedt, R.E., 2011. Risk versus hazard – how to regulate in the 21st century. Eur. J.
Risk Regul. 2, p149–p168.
McGregor, D., Boobis, A., Binaglia, M., Botham, P., Hoffstadt, L., Hubbard, D., Petry, T.,
Riley, A., Schwartz, D., Hennes, C., 2010. Guidance for the classiﬁcation of
carcinogens under the globally harmonised system of classiﬁcation and
labelling of chemicals (GHS). Crit. Rev. Toxicol. 40, 245–285.
Meek, M., Boobis, A., Cote, I., Dellarco, V., Fotakis, G., Munn, S., Seed, J., Vickers, C.,
2014. New developments in the evolution and application of the WHO/IPCS
framework on mode of action/species concordance analysis. J. Appl. Toxicol. 34,
1–18.
Muller, A., Blaude, M.-N., Ihlemann, C., Bjorge, C., Ohlsson, A., Gebel, T., 2012. A
regulatory approach to assess the potency of substances toxic to the
reproduction Regulatory Toxicology and Pharmacology 63, p97–p105.
Roberts, R.A., Crump, K.S., Lutz, W.K., Wiegand, H.-J., Williams, G.M., Harrison, P.T.C.,
Purchase, I.F.H., 2001. Scientiﬁc analysis of the proposed uses of the T25 dose
descriptor in chemical carcinogen regulation. Arch. Toxicol. 75, 507–512.
Sanner, T., Dybing, E., 2005. Comparison of carcinogen hazard characterisation
based on animal studies and epidemiology. Basic Clin. Pharmacol. Toxicol. 96,
66–70.
van Leeuwen, C.J., Vermieire, T.G., 2007. Risk Assessment of Chemicals – An
Introduction, second ed. Springer.
